|Articles|April 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Liberated?

Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.

Articles in this issue

over 25 years ago

Regulation: Two-Track Plan

over 25 years ago

Policy: Tectonic Shift

over 25 years ago

A Matter of Taste

over 25 years ago

Partnerships: Bargaining Biotechs

over 25 years ago

Pediatric Mandate

over 25 years ago

Genentech's Passion for Patients

over 25 years ago

Regulation: OK After All

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.